OTCMKTS:SPHDF Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free SPHDF Stock Alerts $11.70 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$11.70▼$11.7050-Day Range$11.25▼$11.7052-Week Range$9.40▼$13.35VolumeN/AAverage Volume400 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Santhera Pharmaceuticals alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Santhera Pharmaceuticals Stock (OTCMKTS:SPHDF)Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.Read More SPHDF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPHDF Stock News HeadlinesMarch 27, 2024 | markets.businessinsider.comSanthera : Vamorolone NDA Accepted For Priority Review By China' NMPA In Duchenne Muscular DystrophyMarch 27, 2024 | finance.yahoo.comSanthera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPAApril 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 14, 2024 | finance.yahoo.comSanthera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in NeurologyFebruary 3, 2024 | morningstar.comSanthera Pharmaceuticals Holding AG 0QN1January 31, 2024 | finance.yahoo.comSanthera Pharmaceuticals Holding AG (SANN.SW)January 15, 2024 | finance.yahoo.comSanthera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular DystrophyJanuary 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)April 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. January 12, 2024 | finance.yahoo.comSanthera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United KingdomDecember 18, 2023 | finance.yahoo.comSanthera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular DystrophyDecember 7, 2023 | finance.yahoo.comSanthera Appoints Executive Committee Members as it Transitions into Commercial StageOctober 27, 2023 | finance.yahoo.comSanthera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophyOctober 26, 2023 | reuters.comUS FDA approves Santhera's Duschenne drugOctober 13, 2023 | markets.businessinsider.comSanthera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular DystrophyOctober 13, 2023 | markets.businessinsider.comPositive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD TreatmentOctober 13, 2023 | finance.yahoo.comSanthera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophySeptember 8, 2023 | seekingalpha.comSanthera Pharmaceuticals reports 1H resultsSeptember 8, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The CornerSeptember 7, 2023 | finance.yahoo.comSanthera Announces Half-Year 2023 Financial Results and Provides Corporate UpdateJuly 31, 2023 | benzinga.comSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi GroupJuly 31, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)June 29, 2023 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share SplitJune 29, 2023 | finance.yahoo.comSanthera Publishes Timeline of the Reverse Share SplitJune 27, 2023 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General MeetingJune 27, 2023 | finance.yahoo.comShareholders Approve all Board Proposals at Today’s Annual General MeetingJune 21, 2023 | msn.comCatalyst (CPRX) to Gain DMD Drug Licensing Rights From SantheraSee More Headlines Receive SPHDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SPHDF CUSIPN/A CIKN/A Webwww.santhera.com Phone(161) 906-8950FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Thomas Meier Ph.D. (Age 62)Founder & Chairman Comp: $91.83kMr. Dario Eklund (Age 56)Chief Executive Officer Comp: $893.47kMr. Andrew P. Smith CGMA (Age 62)FCMA, Chief Financial Officer Mr. Oliver Strub (Age 61)General Counsel & Secretary Mr. Günther Metz Ph.D. (Age 66)Head Business Development Mr. Shabir Hasham M.D.Chief Medical OfficerMr. Marc SchraderChief Technology OfficerMs. Eva KaliasHead of Investor Relations & CommunicationsMr. Neville Kodkani M.D.Head of Global Marketing & Partner ManagementMs. Sarah Holmes-KlotzHead of People & CultureMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors SPHDF Stock Analysis - Frequently Asked Questions How have SPHDF shares performed in 2024? Santhera Pharmaceuticals' stock was trading at $11.70 on January 1st, 2024. Since then, SPHDF stock has increased by 0.0% and is now trading at $11.70. View the best growth stocks for 2024 here. When did Santhera Pharmaceuticals' stock split? Shares of Santhera Pharmaceuticals reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Santhera Pharmaceuticals? Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SPHDF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santhera Pharmaceuticals Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
